GIGANUCLEASE

Dead / Cancelled — Cancelled — Section 8 (as of 21 Sept 2012)

What this means for you

This registration has been cancelled; it no longer blocks anyone on its own. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
76359549
Registration number
2988451
Mark type
Word mark
Filed
16 Jan 2002
Published for opposition
07 Jun 2005
Registered
30 Aug 2005
Attorney of record
Barry L. Kelmachter

Goods and services

  • Class 001 — Chemicals: Chemicals, biochemical, biotechnological and bacteriological products namely, polypeptides for in vivo and invitro genetic engineering, natural and engineered meganuclease and endonuclease, nucleic acid vectors encoding the natural or engineered meganuclease or endonuclease or nucleic acid vectors comprising their recognition and cleavage site; ready to use genomic recombination system comprised primarily of reagents for scientific use; cells engineered by meganuclease recombination systems for scientific research use and therapeutic use, chemical agents, biochemical, biotechnologic and bacteriological products for use in scientific research laboratories and control laboratories namely cells, reagents, and culture media; diagnostic reagents for scientific use; proteins for use in scientific research; biotechnological preparations used as molecular scissors in scientific research
  • Class 005 — Pharmaceuticals: Pharmaceutical, veterinary, and health care products, namely polypeptides for in vivo and in vitro genetic engineering for use in the treatment of cystic fibrosis, Duchesne muscular dystrophy, and Alpha 1 antitrypsin disease; natural and engineered meganucleases and endonucleases, nucleic acid vectors encoding the natural or engineered meganuclease or endonuclease or nucleic acid vectors comprising their recognition and cleavage site, all for use in the treatment of sickle cell anemia, X-SciD, and Rs-SciD; ready to use genomic recombination system comprised primarily of meganuclease recombination system for use in the treatment of muscular dystrophy; cells engineered by meganuclease recombination system for use in the treatment of genetic and viral disease, microorganism cultures and bacteriological preparations for use in the treatment of genetic and viral disease; chemotherapeutic preparations for use in the treatment of cancer; diagnostic preparations for clinical medical use
  • Class 042 — Scientific and technological services: Scientific and industrial research; research for others in genetic, medical, pharmaceutical, and veterinary fields; research for others in chemistry, biology, biochemistry, molecular biology, bacteriology; scientific analysis services, research and development for others of techniques of biochemical analysis, biological analysis, molecular biology techniques, research and development of new molecules intended for industry, scientific laboratory services; conducting scientific research studies relating to engineering, natural, and engineered meganuclease and endonuclease, and meganuclease recombination systems; licensing of patents and of intellectual property; computer programming for others; and development for others of software programs and multimedia products

Owner

Prosecution history

  • 21 Sept 2012 — CANCELLED SEC. 8 (6-YR)
  • 30 Aug 2005 — EXPARTE APPEAL TERMINATED
  • 30 Aug 2005 — REGISTERED-PRINCIPAL REGISTER
  • 07 Jun 2005 — PUBLISHED FOR OPPOSITION
  • 18 May 2005 — NOTICE OF PUBLICATION
  • 18 Feb 2005 — LAW OFFICE PUBLICATION REVIEW COMPLETED
  • 15 Feb 2005 — ASSIGNED TO LIE
  • 31 Jan 2005 — ASSIGNED TO LIE
  • 26 Jan 2005 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 13 Aug 2004 — JURISDICTION RESTORED TO EXAMINING ATTORNEY
  • 28 Jul 2004 — PAPER RECEIVED
  • 10 Aug 2004 — PAPER RECEIVED
  • 10 Aug 2004 — EX PARTE APPEAL-INSTITUTED
  • 04 Aug 2004 — EXPARTE APPEAL RECEIVED AT TTAB
  • 26 Jan 2004 — FINAL REFUSAL MAILED

View this trademark record on Marksy